ArticleNature cell biology2014
EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.
Article in Nature cell biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 2 syntheses or guidelines pooled it, 235 citations in OpenAlex.
- Multi-omic network analysis identified betacellulin as a novel target of omega-3 fatty acid attenuation of western diet-induced nonalcoholic steatohepatitis.EMBO molecular medicine · 2023Pooled it
- [Guidelines for vaccination of immunocompromised individuals].Wiener klinische Wochenschrift · 2016Guideline
- Trial
- Sexual dimorphism in the liver.Nature reviews. Gastroenterology & hepatology · 2026Review
- Absence of EGFR signalling in granulocytic cells relieves immunosuppression sensitising CRC metastases to immune checkpoint therapy.Cell death and differentiation · 2026Article
- Uncovering the antiproliferative effects of magnolol in liver cancer: a multi-omics study integrating computational chemistry, network pharmacology, bioinformatics and in vitro experimental validations.Molecular diversity · 2026Article
- Inflammatory monocytes constrain YAP-induced cell proliferation.Science advances · 2026Article
- The signaling and regulatory functions of dying cells and cell corpses.Communications biology · 2026Review
- EGFR deletion in myeloid cells reprograms the immunosuppressive landscape of colorectal cancer.Cell death and differentiation · 2026Article
- Article
- Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma.Research square · 2026Article
- CCA-1.1 Destabilizes MYC proteins to induce irreversible anti-proliferative effects in hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2025Article
- CIMT 2025: Report on the 22Human vaccines & immunotherapeutics · 2025Article
- EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Article
- EGFR controls transcriptional and metabolic rewiring in KRASEMBO molecular medicine · 2025Article
- LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1/LTBP1/TGF-β axis.Cell reports. Medicine · 2025Article
- Antioxidant and anticancer properties of fucoidan isolated from Saccharina Japonica brown algae.Scientific reports · 2025Article
- Current and emerging strategies for the prevention of hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2025Review
- EGF receptor in organ development, tissue homeostasis and regeneration.Journal of biomedical science · 2025Review
81 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a frequent cancer with limited treatment options and poor prognosis. Tumorigenesis has been linked with macrophage-mediated chronic inflammation and diverse signalling pathways, including the epidermal growth factor receptor (EGFR) pathway. The precise role of EGFR in HCC is unknown, and EGFR inhibitors have shown disappointing clinical results. Here we discover that EGFR is expressed in liver macrophages in both human HCC and in a mouse HCC model. Mice lacking EGFR in macrophages show impaired hepatocarcinogenesis, whereas mice lacking EGFR in hepatocytes unexpectedly develop more HCC owing to increased hepatocyte damage and compensatory proliferation. Mechanistically, following interleukin-1 stimulation, EGFR is required in liver macrophages to transcriptionally induce interleukin-6, which triggers hepatocyte proliferation and HCC. Importantly, the presence of EGFR-positive liver macrophages in HCC patients is associated with poor survival. This study demonstrates a tumour-promoting mechanism for EGFR in non-tumour cells, which could lead to more effective precision medicine strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.